# ZOSTAVAX(R) Local Registration Trial (V211-019)

> **NCT00444860** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 150 (actual)

## Conditions studied

- Varicella Virus Infection

## Interventions

- **BIOLOGICAL:** Zoster Vaccine, Live, (Oka-Merck)

## Key facts

- **NCT ID:** NCT00444860
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2015-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444860, "ZOSTAVAX(R) Local Registration Trial (V211-019)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00444860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*